• vcard
D 312.873.3633
F 312.602.3922
  • Education
    • J.D., cum laude, UIC John Marshall Law School, 2011, Order of John Marshall; Fred F. Herzog Scholarship; Dean's Scholarship
    • Ph.D., University of Wisconsin, 2002, Genetics
    • B.A., University of California, Berkeley, 1995, with High Honors and with Distinction in General Scholarship
  • Bar Jurisdictions
    • Illinois, 2011
    • Admitted to practice before the United States Patent and Trademark Office

Dr. Ron Galant brings all facets of his legal, biotech industry and academic research experience to bear when counseling clients on a variety of intellectual property issues.

Whether it's patent counseling, intellectual property licensing, patent opinions, or intellectual property due diligence, clients can depend on Ron's unique perspective to achieve their goals.

Ron has significant experience in the following areas:

  • Patent prosecution and preparation in many technology areas, including pharmaceuticals, biologics, and molecular and medical diagnostics
  • Intellectual property licensing and other technology transfer agreements
  • Patent invalidity, freedom to operate, and non-infringement opinions
Ron developed his patent counseling expertise while working as an attorney and a patent agent at Polsinelli. He also gained pharmaceutical industry experience designing clinical trials and preparing clinical study reports.

Previously, Ron worked in business development at a biotechnology company that had developed an industrial-scale gene-screening platform. His education includes multi-disciplinary graduate research that led to completion of a doctorate and publications in leading scientific journals.
  • Wrote and prosecuted patent applications leading to issued patents in multiple jurisdictions in a variety of technology areas.
  • Drafted an intellectual property license agreement for a client to license a protein-based drug technology.
  • Wrote a patent invalidity opinion for a major generic drug company in preparation for a first-to-file Abbreviated New Drug Application.
  • Performed intellectual property due diligence in merger and acquisition of a target technology company.
  • Reviewed and revised technology licensing contracts with Fortune 500 companies for client's web-based virtual event presentation platform.
text icon Publications & Presentations
A Multi-Center, Open Label Study to Evaluate Satisfaction and Menopausal Quality of Life in Women Using Transdermal Estradiol/Norethindrone Acetate Therapy for the Management of Menopausal Signs and Symptoms
Gynecologic and Obstetric Investigation
text icon Publications & Presentations
Hox Repression of a Target Gene: Extradenticle-Independent, Additive Action Through Hox Repression of a Target Gene: Extradenticle-Independent, Additive Action Through Multiple Monomer Binding Sites
First Author
text icon Publications & Presentations
Evolution of a Novel Transcriptional Repression Domain in the Ultrabithorax Hox Protein in Insects
First Author
Related News